Comparison of treatment with insulin glargine and insulin Humulin NPH


如何引用文章

全文:

详细

The comparative analysis of the effectiveness of basal insulin analog (glargine) and classical longer-acting insulin - neutral protamine Hagedorn (Humulin NPH) is presented. The data indicates that glycemic control by these drugs led to similar levels of glycosylated hemoglobin in patients. The mitogenic potential of insulin glargine requires additional investigation. Cost benefit analysis show much lower cost of insulin Humulin NPH, and extensive experience of its safe use was demonstrated.

参考

  1. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous infusion of insulin lispro. Diabetes 2000;49:2142-48.
  2. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51.
  3. Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-86.
  4. Yki-Jarvinnen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-36.
  5. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-59.
  6. Pugh JA, Wagner ML, Sawyer J, et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? Diabetes Care 1992;15:953-59.
  7. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991;115:45-53.
  8. Yki-Jarvinnen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67.
  9. Wright A, Burden AC, Paisey RB, et al. Sulfolylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes mellitus in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-36.
  10. Riddle MC, Rosenstock J, Gerich JE, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy in type 2 diabetic patients. Diabetes Care 2003;26:3080-86.
  11. Rosenstock J, Schwartz SL, Clark CM, et al. Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24(4):631-36.
  12. Riddle MC, Rosenstock J, Gerich J. The treat-to-Target Trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-86.
  13. Rosenstock J, Ahmann AJ, Colon J, et al: Advancing Insulin Therapy in Type 2 Diabetes Previously Treated with Glargine Plus Oral Agents. Diabetes Care 2008;31:20-25.
  14. Horvath K, Jeitler K, Berghold A, et al.: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 3:CD005613, 2009.
  15. Kurtzhals P, Schaffer L, Sorenson A, et al. Correlations of Receptor Binding and Metabolic and Mitogenic Potencies of Insulin Analogs Designed for Clinical Use. Diabetes 2000;49:999-1005.
  16. Slieker LJ, Brooke GS, Dimarchi RD, et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997;40:54-61.
  17. Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted actions in pigs. Diabetologia 1996;39:281-88.
  18. Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 1996;85:304-08.
  19. Lammers R, Gray A, Schlessinger J, et al. Differential signaling potential of insulin and IGF-I receptor cetoplasmic domains. EMBO J 1989;8:1369-75.
  20. Markussen J. Human Insulin by Tryptic Transpeptidation of Porcine Insulin and Biosynthetic Precursors. Lancaster, U.K., MTP, 1987;1-171.
  21. Markussen J, Damgaard U, Diers I, et al. Biosynthesis of human insulin in yeast via single-chain precursors. In Peptides 1986. Theodoroupoulos D, Ed. Berlin, Walter de Cruyters 1987;189-94.
  22. Chan SJ, Weiss J, Konrad M, et al. Biosynthesis and periplasmic segregation of human pro insulin in Escherichia coli. Proc Nath Acad Sci USA 1981;78:5401-05.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2010
##common.cookie##